Get the Stockscreener App
3.83
3.51%
+0.13
Relmada Therapeutics Inc stock is currently priced at $3.83, with a 24-hour trading volume of 80,013.
It has seen a +3.51% increased in the last 24 hours and a -18.34% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.72 pivot point. If it approaches the $3.87 resistance level, significant changes may occur.
Previous Close:
$3.70
Open:
$3.69
24h Volume:
80,013
Market Cap:
$115.57M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.8949
EPS:
-4.28
Net Cash Flow:
$-51.66M
1W Performance:
-4.25%
1M Performance:
-18.34%
6M Performance:
+21.97%
1Y Performance:
+43.98%
1D Range:
$3.62
$3.87
52W Range:
$2.3601
$7.2225
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646-876-3459
Address
880 Third Avenue, 12th Floor, New York, NY
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Relmada Therapeutics Inc (RLMD) Net Income 2024
RLMD net income (TTM) was -$98.79 million for the quarter ending December 31, 2023, a +37.09% increase year-over-year.
Relmada Therapeutics Inc (RLMD) Cash Flow 2024
RLMD recorded a free cash flow (TTM) of -$51.66 million for the quarter ending December 31, 2023, a +50.23% increase year-over-year.
Relmada Therapeutics Inc (RLMD) Earnings per Share 2024
RLMD earnings per share (TTM) was -$3.27 for the quarter ending December 31, 2023, a +38.30% growth year-over-year.
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ence Chuck | CA and CO |
Jan 31 '24 |
Buy |
4.05 |
13,670 |
55,429 |
38,970 |
| Shenouda Maged | Chief Financial Officer |
Jan 31 '24 |
Buy |
4.06 |
6,875 |
27,943 |
34,903 |
| TRAVERSA SERGIO | Chief Executive Officer |
Jan 30 '24 |
Buy |
3.90 |
40,999 |
159,949 |
216,564 |
| Shenouda Maged | Chief Financial Officer |
Jan 30 '24 |
Buy |
3.89 |
15,000 |
58,323 |
28,028 |
| Ence Chuck | CA and CO |
Jan 30 '24 |
Buy |
3.87 |
14,500 |
56,053 |
25,300 |
| TRAVERSA SERGIO | Chief Executive Officer |
Jan 29 '24 |
Buy |
3.71 |
31,541 |
117,036 |
175,565 |
| Shenouda Maged | Chief Financial Officer |
Jan 29 '24 |
Buy |
3.65 |
10,800 |
39,450 |
13,028 |
| Ence Chuck | CA and CO |
Jan 29 '24 |
Buy |
3.65 |
10,800 |
39,438 |
10,800 |
| O'Gorman Cedric | Chief Medical Officer |
May 23 '23 |
Buy |
3.18 |
10,000 |
31,800 |
10,121 |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
1.53%
3.38%
Cap:
|
Volume (24h):